Nina Hentzen is a Senior Scientist in Early Development Bioconjugates at Lonza in Visp, Switzerland. She is responsible for leading preclinical bioconjugation projects and establishing and managing collaborations with technology partners to enhance innovation in bioconjugates development and manufacturing. Nina is an organic chemist by training and holds a PhD in peptide chemistry from ETH Zurich. Prior to joining Lonza, she was a Swiss National Science Foundation postdoctoral fellow at UC San Francisco where she was working on computational protein design.
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.